Lacosamide

CAS 175481-36-4 33 current records 3 historicalSmall Molecule

Who holds supplier records for Lacosamide? 33 organisations hold a current record for Lacosamide: an active US FDA Type II Drug Master File or a CEP. A further 3 organisations have only historical (inactive) DMF filings. 25 of them hold a valid EU Certificate of Suitability. Recorded organisation countries for current records: India (25), China (3), Italy (1) and Netherlands (1); not recorded for 3.

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records

Cite as: PharmaTek, “Lacosamide: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/lacosamide

Reading the evidence

  • 33 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • Most recorded organisations are in India

    25 of the 30 current records with a recorded country list India. Organisation country is not necessarily the manufacturing site.

  • 17 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

  • US product patents listed

    The latest patent listed in the FDA Orange Book for an approved product containing Lacosamide expires 5 Jun 2040. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.

Current records (33)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Lacosamide. Country is the organisation's recorded country, not necessarily the manufacturing site.

India25China3Italy1Netherlands1Country not recorded for 3
Need Lacosamide sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

Valid CEP holder entries (25)

Certificates of Suitability on the EDQM register for Lacosamide, including the salts, esters and hydrates the register lists separately; each row shows the substance as named on the certificate. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer. 29 certificates in total, including withdrawn, expired, suspended and repeat certificates.

HolderCountryCertificateIssuedEU GMP at holder's address
WISDOM PHARMACEUTICAL CO., LTD. HaimenCN
CEP 2020-283 - Rev 01
Lacosamide
Nov 2026—
MSN PHARMACHEM PRIVATE LIMITED SangareddyIN
CEP 2026-260 - Rev 00
Lacosamide, Route code-LS, crystalline form-I
Sept 2026—
CHROMO LABORATORIES INDIA PRIVATE LIMITED PashamylaramIN
CEP 2025-124 - Rev 00
Lacosamide
Aug 2026—
VIYASH SCIENTIFIC LIMITED HyderabadIN
CEP 2022-353 - Rev 02
Lacosamide
Jul 2026—
INDOCO REMEDIES LIMITED MumbaiIN
CEP 2021-147 - Rev 03
Lacosamide, Process II
Jun 2026—
CAMBREX PROFARMACO MILANO S.R.L. PaulloIT
CEP 2019-184 - Rev 01
Lacosamide
May 2026Inspected Sept 2025
Italy
ALIVUS LIFE SCIENCES LIMITED MumbaiIN
CEP 2021-163 - Rev 03
Lacosamide
May 2026—
MACLEODS PHARMACEUTICALS LIMITED MumbaiIN
CEP 2018-151 - Rev 02
Lacosamide
May 2026—
BEIJING HOPE PHARMACEUTICAL CO., LTD. BeijingCN
CEP 2025-593 - Rev 00
Lacosamide, Shijiazhuang Site, process B
Apr 2026—
HETERO DRUGS LIMITED HyderabadIN
CEP 2018-099 - Rev 04
Lacosamide, Form-I
Feb 2026—
JUBILANT BIOSYS LIMITED MysuruIN
CEP 2019-049 - Rev 02
Lacosamide
Jan 2026—
CHIERON ACTIVE INGREDIENTS PRIVATE LIMITED HyderabadIN
CEP 2019-048 - Rev 02
Lacosamide
Dec 2025—
VASUDHA PHARMA CHEM LIMITED HyderabadIN
CEP 2024-405 - Rev 00
Lacosamide
Nov 2025—
DIVI'S LABORATORIES LIMITED HyderabadIN
CEP 2020-437 - Rev 03
Lacosamide
Oct 2025—
EMNAR PHARMA PRIVATE LIMITED HyderabadIN
CEP 2023-438 - Rev 00
Lacosamide
Oct 2025—
LEE PHARMA LIMITED HyderabadIN
CEP 2019-223 - Rev 01
Lacosamide
Oct 2025—
APITORIA PHARMA PRIVATE LIMITED HyderabadIN
CEP 2024-128 - Rev 02
Lacosamide, Process II
Jun 2025—
ALEMBIC PHARMACEUTICALS LIMITED VadodaraIN
CEP 2018-276 - Rev 02
Lacosamide, Form-I
May 2025—
METROCHEM API PRIVATE LIMITED HyderabadIN
CEP 2023-365 - Rev 01
Lacosamide
Jan 2025—
INTAS PHARMACEUTICALS LIMITED AhmedabadIN
CEP 2018-247 - Rev 02
Lacosamide, Form I, milled
Nov 2024—
ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. LinhaiCN
CEP 2022-024 - Rev 01
Lacosamide
Sept 2024Inspected May 2026
Italy
AALIDHRA PHARMACHEM PRIVATE LIMITED NandesariIN
CEP 2023-039 - Rev 01
Lacosamide
Aug 2024—
HIKAL LIMITED BangaloreIN
CEP 2020-107 - Rev 03
Lacosamide
May 2024Inspected Nov 2025
Switzerland
RAGHAVA LIFE SCIENCES PRIVATE LIMITED HyderabadIN
CEP 2022-236 - Rev 00
Lacosamide
Nov 2023—
SHANDONG LONCOM PHARMACEUTICAL CO., LTD QiheCN
R0-CEP 2021-451 - Rev 01
Lacosamide
May 2023—

The GMP column shows the most recent EU GMP certificate issued for the same address as the holder, joined on the EMA location identifier printed on both documents (EudraGMDP, re-read about once a quarter; withdrawn certificates are excluded). A dash means no certificate carries that identifier, not that the site is uninspected. The holder's address is not necessarily where the substance is made.

Certification Online Database. European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, (2026), URL: https://extranet.edqm.eu/publications/recherches_CEP.shtml. Accessed 16 Nov 2026. Reproduced with permission and unaltered. The EDQM and the Council of Europe accept no liability for any consequence arising from its use.

Historical records (3)

Organisations whose Type II DMFs for Lacosamide are no longer active. These show a past filing, not current supply.

Show all 3 historical records
  • LUPIN MANUFACTURING SOLUTIONS LTD
    Inactive DMF 27835 · filed Dec 2013
  • CURIA MISSOURI INC
    Inactive DMF 26382 · filed Sept 2012
  • India · Inactive DMF 24599 · filed Feb 2011

US product patents and exclusivity

The FDA Orange Book lists patents and exclusivities for specific approved products (81 listed products contain Lacosamide). The latest listed patent expires 5 Jun 2040. The latest listed exclusivity ended 28 Apr 2026. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.

Overview

Lacosamide is an antiepileptic drug used primarily to treat partial-onset seizures. It works by selectively enhancing slow inactivation of voltage-gated sodium channels, thereby stabilizing hyperexcitable neuronal membranes.

Chemical identity

IUPAC name
(2R)-2-acetamido-N-benzyl-3-methoxypropanamide
Canonical SMILES
CC(=O)N[C@H](COC)C(=O)NCC1=CC=CC=C1
InChIKey
VPPJLAIAVCUEMN-GFCCVEGCSA-N
Synonyms
Vimpat API, (r)-lacosamide 1, add-243037, add243037, erlosamide, motpoly, spm-927, spm927, vimpat

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Physiologic effect
Decreased Central Nervous System Disorganized Electrical Activity

Therapeutic areas

NeurologyEpilepsySeizure Disorders

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Lacosamide?

33 organisations hold an active US FDA Type II Drug Master File or a CEP for Lacosamide: APITORIA PHARMA PRIVATE LTD (India), BEIJING HOPE PHARMACEUTICAL CO LTD, INDOCO REMEDIES LTD (India), MSN PHARMACHEM PRIVATE LTD (India), Alembic Pharmaceuticals Limited (India), ALIVUS LIFE SCIENCES LTD (India), CAMBREX PROFARMACO MILANO SRL (Italy) and CHIERON ACTIVE INGREDIENTS PRIVATE LTD (India), and 25 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Lacosamide Drug Master Files are active?

APITORIA PHARMA PRIVATE LTD (DMF 39650, 26313), BEIJING HOPE PHARMACEUTICAL CO LTD (DMF 40011, 33678), INDOCO REMEDIES LTD (DMF 29476, 36788), MSN PHARMACHEM PRIVATE LTD (DMF 26270, 34737), Alembic Pharmaceuticals Limited (DMF 26349), ALIVUS LIFE SCIENCES LTD (DMF 26323), CAMBREX PROFARMACO MILANO SRL (DMF 29763) and CHIERON ACTIVE INGREDIENTS PRIVATE LTD (DMF 33552) and 21 more. The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

What do the historical Lacosamide records mean?

3 organisations have only inactive Type II DMFs for Lacosamide. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.

Does Lacosamide have a European Certificate of Suitability?

Yes. 25 organisations hold a valid CEP for Lacosamide on the EDQM register, including WISDOM PHARMACEUTICAL CO., LTD. Haimen (CN), MSN PHARMACHEM PRIVATE LIMITED Sangareddy (IN), CHROMO LABORATORIES INDIA PRIVATE LIMITED Pashamylaram (IN), VIYASH SCIENTIFIC LIMITED Hyderabad (IN), INDOCO REMEDIES LIMITED Mumbai (IN) and CAMBREX PROFARMACO MILANO S.R.L. Paullo (IT) and 19 more. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.

Does the FDA Orange Book list patents for products containing Lacosamide?

Yes. The latest patent listed for an approved US product containing Lacosamide expires 5 Jun 2040, across 81 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.

How do I qualify a Lacosamide supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Lacosamide?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.